Abstract
The current treatment for natural killer/T-cell lymphoma (NKTL) among advanced/relapsed patients is unsatisfying, thereby highlighting the need for novel therapeutic targets. B‐cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A), as a transcription factor, is oncogenic in several neoplasms. However, its function in NKTL remains unclear. Quantitative real-time polymerase chain reaction and Western blot analysis were used to measure the BCL11A expression levels among NKTL patients and in NKTL cell lines. Natural killer (NK) cells from healthy subjects were used as negative control. Transient transfection with small interfering RNA was used to knockdown the expression in NKTL cell lines. Samples and clinical histories were collected from 343 NKTL patients (divided into test and validation groups) to evaluate the clinical value of BCL11A expression level. The BCL11A expression was upregu\\lated among NKTL patients and in NKTL cell lines. Reduced cell proliferation and increased apoptosis were observed after silencing BCL11A in NKTL cell lines. BCL11A expression level was correlated with RUNX3, c-MYC, and P53 in NKTL. Notably, a high BCL11A expression was correlated with unfavorable clinical characteristics and predicted poor outcomes in NKTL. In conclusion, BCL11A was overexpressed in NKTL, while its upregulation promoted tumor development. Therefore, BCL11A expression level may be a promising prognostic biomarker for NKTL.
Highlights
Natural killer/T-cell lymphoma (NKTL) is an aggressive, rare disease that is more frequently observed in Asia and South America than in North America and Europe (Tse and Kwong, 2016)
The results suggest that the B‐cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A) messenger RNA (mRNA) expression level was upregulated in the cell lines and samples of natural killer/T-cell lymphoma (NKTL) patients relative to normal NK cells (Figure 1A)
A higher BCL11A protein expression level was observed in NKTL cell lines (SNK-1, NK-YS, HANK1, and KHYG-1) than in normal NK cells (Figure 1B)
Summary
Natural killer/T-cell lymphoma (NKTL) is an aggressive, rare disease that is more frequently observed in Asia and South America than in North America and Europe (Tse and Kwong, 2016). NKTL is a neoplastic disease characterized by T and natural killer (NK) cells with Epstein–Barr virus (EBV) infection (Tse and Kwong, 2017). Much progress has been reported in the development. BCL11A in Natural Killer/T-Cell Lymphoma of NKTL treatment strategies. The first-line treatment for earlystage NKTL is combined chemotherapy and radiotherapy (RT) (sequentially or concurrently) (Bi et al, 2013; Wang et al, 2013). An optimal therapy for patients with late-stage or relapsed NKTL has not yet been formulated. Advanced/relapsed NKTL patients continue to demonstrate poor outcomes.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
